Fred Kamal's most recent trade in 4D Molecular Therapeutics Inc was a trade of 260,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 11, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Kamal Fred | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 260,000 | 260,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Fred Kamal | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Fred Kamal | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Fred Kamal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Fred Kamal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) |